I’m curious to hear what others think about this latest cap raise. We’re now back at 2018 levels, which I honestly didn’t expect to see again. With a market cap of around $66 million, I can’t help but feel the company is undervalued—especially considering the strength of the drug candidate we’re developing.
Looking at what’s been achieved since 2018—efficacy data, a stronger IP position, and a growing pipeline—it’s clear we’ve come a long way. We also seem to be edging closer to potential commercialization.That said, I understand sentiment among holders is still mixed, particularly after earlier delays and unmet expectations. What’s the general feeling heading into this raise?Do people see commercialization as a realistic next step, particularly in light of the TGA Special Access Scheme results?
With uncertainty around the current Trump administration’s policy stance, could shifting trials to Indonesia be a more viable and strategic path?
I’m also keen to hear what people make of the directors taking up their entitlements in this offer—does it suggest insider confidence? And what about the $5.0 million commitment from an Australian-based private investor—does that raise eyebrows for anyone else?
RCE Price at posting:
28.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)